SWISS-MODEL will be unavailable for most of Thursday, 13th October (due to the physical relocation of hardware).
Long running jobs will fail after 08:45 CEST.

Q03181 (PPARD_HUMAN) Homo sapiens (Human)

Peroxisome proliferator-activated receptor delta UniProtKBInterProSTRINGInteractive Modelling

441 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4); 1 identical sequence: Homo sapiens: A0A024RCW6

Available Structures

52 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP401homo-2-mer170-441
B7G;401;
Assess
Human peroxisome proliferator-activated receptor (PPAR) delta ligand binding domain in complex with…homo-2-mer171-441
B7G;K55;
Assess
human peroxisome proliferator-activated receptor (PPAR) delta ligand binding domain in complex with…homo-2-mer171-441
82K;B7G;
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORShomo-2-mer171-441
EPA;
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORShomo-2-mer171-441
433;
Assess
Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP204homo-2-mer170-440
B7G;K55;
Assess
Human peroxisome proliferator-activated receptor (PPAR) delta ligand binding domain in complex with…homo-2-mer172-441
B7G;820;
Assess
Human peroxisome proliferator-activated receptor (PPAR) delta ligand binding domain in complex with…homo-2-mer172-441
B7G;81O;
Assess
Human Peroxisome proliferator-activated receptor (PPAR) delta in complexed with a potent and select…homo-2-mer173-441
8RR;K;CL;PGO;JZR;
Assess
Human PPAR delta ligand binding domain in complex with a synthetic agonist H11homo-2-mer173-441
85B;
Assess
Co-crystal structure of Inhibitor compound MA-211 in complex with human PPARdelta LBDhomo-2-mer171-439
1KF;
Assess
Human Nuclear Receptor-Ligand Complex 1homo-2-mer174-441
B7G;VCA;
Assess
Co-crystal structure of an Inhibitor in complex with human PPARdelta LBDhomo-2-mer171-438
9LU;
Assess
PPARdelta complexed with an anthranilic acid partial agonisthomo-2-mer172-439
IOD;DY6;
Assess
Co-crystal structure of Inhibitor compound in complex with human PPARdelta LBDhomo-2-mer172-438
89L;
Assess
Crystal Structure of PPAR-delta complexhomo-2-mer175-441
L41;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 4monomer170-440
7UY;B7G;PGO;PEG;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 11monomer170-440
B7G;7SM;PGO;PEG;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 7monomer170-440
B7G;7U1;PGO;
Assess
Crystal structure PPAR delta binding GW0742monomer171-441
GW0;GOL;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 3monomer170-440
7V4;B7G;PGO;PEG;K;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 12monomer170-439
7SS;PGO;PEG;B7G;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 2monomer170-439
B7G;7V1;PGO;PEG;
Assess
Human PPARdelta ligand-binding domain in complexed with GW501516monomer170-439
B7G;PGO;PEG;7T1;
Assess
Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd)LBD in Complex with DN…monomer171-440
9RF;B7G;PE3;
Assess
Crystal structure of PPAR delta complexed with GW2331monomer170-439
IOD;331;B7G;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 1monomer173-441
7UJ;B7G;PGO;PEG;K;
Assess
X-ray structure of human PPAR delta ligand binding domain-pemafibrate co-crystals obtained by co-cr…monomer173-441
P7F;BOG;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 6monomer173-441
B7G;7TY;PEG;PGO;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 9monomer171-439
B7G;7U7;PGO;PEG;
Assess
Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd) in Complex with a Ful…monomer171-439
B7G;D32;
Assess
Structure of PPARdelta with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acidmonomer172-440
ET1;1BO;
Assess
Structural basis for iloprost as a dual PPARalpha/delta agonistmonomer173-441
IL2;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 10monomer172-439
7UA;PGO;PEG;B7G;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 14monomer174-441
B7G;7SY;PEG;PGO;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 5monomer172-439
7TV;PGO;PEG;B7G;
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomer173-440
WLM;1PE;
Assess
X-ray structure of human PPAR delta ligand binding domain-bezafibrate co-crystals obtained by co-cr…monomer174-440
BOG;PEM;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 8monomer173-439
7U4;B7G;PGO;PEG;
Assess
PPARd complexed with a phenoxyacetic acid partial agonistmonomer173-439
3EQ;JZR;IOD;
Assess
3,4,5-Trisubstituted Isoxazoles as Novel PPARdelta Agonists: Part2monomer174-440
GNI;
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomer174-440
08S;BOG;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 16monomer174-439
7UG;PEG;PGO;
Assess
Human Nuclear Receptor-Ligand Complex 2monomer175-440
CA;B7G;VCA;
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORSmonomer175-440
Assess
PPAR Delta in complex with azppard02monomer175-440
3OZ;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 15monomer174-438
7UD;PEG;PGO;B7G;
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 13monomer174-438
B7G;PGO;7SV;
Assess
Human Nuclear Receptor-Ligand Complex 1monomer175-439
B7G;VCA;
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomer176-440
Z00;BOG;
Assess
Ligand binding domain of PPAR delta receptor in complex with a partial agonistmonomer174-438
1FA;
Assess
Solution structure of the C4-type zinc finger domain from human Peroxisome proliferator-activated r…monomer72-146
ZN;
Assess

7 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3dzy.1.Bmonomer0.7371-441
ZN;65.59
Assess
4nqa.1.Amonomer0.5669-438
ZN;31.27
Assess
3dzu.1.Amonomer0.5571-437
ZN;32.61
Assess
4iqr.2.Amonomer0.5472-439
ZN;29.75
Assess
5uan.1.Amonomer0.5472-439
ZN;31.27
Assess
7kw7.1.Fmonomer0.52177-439
21.92
Assess
4iqr.2.Bmonomer0.5272-439
ZN;29.75
Assess

14 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 23e00.1.Bmonomer0.6770-360
ZN;64.60
Assess
Isoform 25uan.1.Bmonomer0.5873-360
ZN;30.28
Assess
Isoform 24nqa.1.Amonomer0.5370-360
ZN;34.43
Assess
Isoform 23dzu.1.Amonomer0.5271-360
ZN;35.66
Assess
Isoform 25uan.1.Amonomer0.5172-360
ZN;34.43
Assess
Isoform 24iqr.2.Bmonomer0.5072-360
ZN;31.93
Assess
Isoform 33e00.1.Bmonomer0.7231-402
ZN;65.42
Assess
Isoform 33dzu.1.Amonomer0.5732-398
ZN;32.92
Assess
Isoform 34nqa.1.Amonomer0.5728-399
ZN;31.69
Assess
Isoform 35uan.1.Amonomer0.5533-400
ZN;31.69
Assess
Isoform 34iqr.2.Bmonomer0.5333-400
ZN;29.25
Assess
Isoform 34iqr.2.Amonomer0.5333-400
ZN;29.25
Assess
Isoform 43et2.1.Amonomer0.8374-342
ET1;1BO;100.00
Assess
Isoform 43dzy.1.Bmonomer0.7236-343
60.91
Assess